Company intelligence / Profile preview
Granite Bio
Basel, Switzerlandgranitebio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
GRT-001 is currently in Phase 1a testing in healthy volunteers and is expected to enter a Phase 1b trial in patients with inflammatory bowel disease later in 2025. In non-human primate studies, GRT-001 efficiently and dose-dependently depleted pro-inflammatory monocytes with good tolerability. GRT-002 is in preclinical development and expected to enter clinical trials in 2026[5][8].
- Therapeutic areas
- GastroenterologyDermatologyRheumatologyImmunology
- Modalities
- Therapeutic antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaboration with Versant's Ridgeline Discovery Engine
Beyond the preview
Go deeper on Granite Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granite Bio.